Boya Biology (300294.SZ) plans to invest 60 million yuan in the establishment of the second phase of China Resources Pharmaceutical Industry Investment Fund.

Intelligent Finance and Economics APP news, Boya Biological (300294.SZ) announced that the company plans to jointly establish the innovative investment fund partnership enterprise (limited partnership) of CR Pharmaceutical (Chengdu) managed by ordinary partners such as CR Pharmaceutical (Chengdu) Enterprise Management Partnership Enterprise (Limited Partnership) (tentative name, subject to industrial and commercial approval name) and CR Pharmaceutical Investment Co., Ltd. The fund has a scale of 1 billion RMB, and Shenzhen CR Capital Equity Investment Co., Ltd. is the fund manager. The company plans to invest a total of 60 million RMB with its own funds as a limited partner, holding 6% of the fund's property share.